Astellas Pharma

CompanyJapan

Astellas Pharma develops 3 assets, the furthest approved (celecoxib in acute pain). Mostly small molecule and cell therapy acting on inflammation, PTGS2 and OPRM1; based in Japan.

Assets
3
Furthest
Approved
Trials
50
Signals
0

Pipeline

3

  • celecoxib

    Selective cyclooxygenase-2 inhibitor reducing prostaglandin synthesis to relieve pain and inflammation

    ApprovedSmall moleculeInflammationPTGS2acute painadenomatous polyposis coli

  • fezolinetant

    Neurokinin 3 (NK3) receptor antagonist that blocks neurokinin B binding in the hypothalamus.

    ApprovedSmall moleculeTACR3hot flashesmenopause

  • ASP7317

    Replaces degenerate retinal pigment epithelium cells with embryonic stem cell-derived RPE cells.

    Phase 1Cell therapyStem cell maintenancegeographic atrophy

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms5
  • Trials66
  • Signals1
  • Integrity notices4
  • Similar companies6

Updated 7 Oct 2026 · 99 sources

Intelligence